TLR signaling by tumor and immune cells: a double-edged sword

B Huang, J Zhao, JC Unkeless, ZH Feng, H Xiong - Oncogene, 2008 - nature.com
The tumor cell signaling pathways that trigger the uncontrolled proliferation, resistance to
apoptosis, metastasis and escape from immune surveillance are partially understood. Toll …

Tumor immunoediting and immunosculpting pathways to cancer progression

JM Reiman, M Kmieciak, MH Manjili… - Seminars in cancer …, 2007 - Elsevier
Recent studies have suggested that a natural function of the immune system is to respond
and destroy aberrant, dysfunctional cells by a process called immunosurveillance. These …

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

Y Hailemichael, Z Dai, N Jaffarzad, Y Ye, MA Medina… - Nature medicine, 2013 - nature.com
To understand why cancer vaccine–induced T cells often do not eradicate tumors, we
studied immune responses in mice vaccinated with gp100 melanoma peptide in incomplete …

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

W Peng, C Liu, C Xu, Y Lou, J Chen, Y Yang, H Yagita… - Cancer research, 2012 - AACR
Adoptive cell transfer (ACT) is considered a promising modality for cancer treatment, but
despite ongoing improvements, many patients do not experience clinical benefits. The tumor …

[HTML][HTML] Dendritic cells in the cancer microenvironment

Y Ma, GV Shurin, Z Peiyuan, MR Shurin - Journal of Cancer, 2013 - ncbi.nlm.nih.gov
The complexity of the tumor immunoenvironment is underscored by the emergence and
discovery of different subsets of immune effectors and regulatory cells. Tumor-induced …

Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington… - Clinical Cancer …, 2012 - AACR
Purpose: In this study, we assessed the specific role of BRAF (V600E) signaling in
modulating the expression of immune regulatory genes in melanoma, in addition to …

Cellular and molecular mechanisms in cancer immune escape: a comprehensive review

A Bhatia, Y Kumar - Expert review of clinical immunology, 2014 - Taylor & Francis
Immune escape is the final phase of cancer immunoediting process wherein cancer
modulates our immune system to escape from being destroyed by it. Many cellular and …

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement

S Brandau, H Suttmann - Biomedicine & Pharmacotherapy, 2007 - Elsevier
Over the last three decades, intravesical immunotherapy with the biological response
modifier Mycobacterium bovis bacillus Calmette–Guérin (BCG) has been established as the …

Human dendritic cells in cancer

E Kvedaraite, F Ginhoux - Science immunology, 2022 - science.org
Dendritic cells (DCs) are professional antigen-presenting cells, orchestrating innate and
adaptive immunity during infections, autoimmune diseases, and malignancies. Since the …

Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain

G Lizée, G Basha, J Tiong, JP Julien, M Tian… - Nature …, 2003 - nature.com
Dendritic cells (DCs) can present extracellularly derived antigens in the context of major
histocompatibility complex (MHC) class I molecules, a process called cross-presentation …